The status of Nrf2-based therapeutics: current perspectives and future prospects

by Irina G Gazaryan, Bobby Thomas
Published 2016-01-01

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

by Andrey A. Poloznikov, Stepan A. Nersisyan, Dmitry M. Hushpulian, Dmitry M. Hushpulian, Eliot H. Kazakov, Alexander G. Tonevitsky, Sergey V. Kazakov, Valery I. Vechorko, Sergey V. Nikulin, Julia A. Makarova, Irina G. Gazaryan, Irina G. Gazaryan, Irina G. Gazaryan, Irina G. Gazaryan
Published 2021-01-01

Challenges and Limitations of Targeting the Keap1-Nrf2 Pathway for Neurotherapeutics: Bach1 De-Repression to the Rescue

by Dmitry M. Hushpulian, Dmitry M. Hushpulian, Navneet Ammal Kaidery, Navneet Ammal Kaidery, Manuj Ahuja, Manuj Ahuja, Manuj Ahuja, Andrey A. Poloznikov, Sudarshana M. Sharma, Irina G. Gazaryan, Irina G. Gazaryan, Irina G. Gazaryan, Irina G. Gazaryan, Bobby Thomas, Bobby Thomas, Bobby Thomas, Bobby Thomas
Published 2021-04-01

A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties

by Thong C. Ma, Brett Langley, Brian Ko, Na Wei, Irina G. Gazaryan, Neela Zareen, Darrell J. Yamashiro, Dianna E. Willis, Rajiv R. Ratan
Published 2013-01-01